Evidence map›Paper›PMID 39779672›Full record

ArticleNature communications2025

YAP-driven malignant reprogramming of oral epithelial stem cells at single cell resolution.

Farhoud Faraji, Sydney I Ramirez, Lauren M Clubb, Kuniaki Sato, Valeria Burghi, Thomas S Hoang, Adam Officer, Paola Y Anguiano Quiroz, William M G Galloway, Zbigniew Mikulski and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. The Regulation and Function of Hippo/YAP Pathway in Cancer.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Farhoud FarajiDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego Health, La Jolla, CA, 92037, USA. f1faraji@health.ucsd.edu.ORCID http://orcid.org/0000-0001-5078-813X
Sydney I RamirezDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego Health, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0002-7166-5195
Lauren M ClubbUniversity of California San Diego, Biomedical Sciences Graduate Program, La Jolla, CA, 92093, USA.
Kuniaki SatoGleiberman Head and Neck Cancer Center, Moores Cancer Center, University of California San Diego Health, La Jolla, CA, 92037, USA.ORCID http://orcid.org/0000-0001-6014-1911
Valeria BurghiDepartment of Pharmacology, University of California San Diego, School of Medicine, La Jolla, CA, 92093, USA.
Thomas S HoangUniversity of California San Diego, Biomedical Sciences Graduate Program, La Jolla, CA, 92093, USA.
Adam OfficerUniversity of California San Diego, Bioinformatics and Systems Biology Graduate Program, La Jolla, CA, 92093, USA.
Paola Y Anguiano QuirozGleiberman Head and Neck Cancer Center, Moores Cancer Center, University of California San Diego Health, La Jolla, CA, 92037, USA.
William M G GallowayDepartment of Chemical and Biomolecular Engineering, University of California Irvine, Irvine, CA, 92697, USA.
Zbigniew MikulskiLa Jolla Institute for Immunology, La Jolla, CA, 92037, USA.
Kate Medetgul-ErnarGleiberman Head and Neck Cancer Center, Moores Cancer Center, University of California San Diego Health, La Jolla, CA, 92037, USA.
Pauline MarangoniDepartment of Orofacial Sciences and Program in Craniofacial Biology, University of California San Francisco, San Francisco, CA, 94143, USA.
Kyle B JonesDepartment of Orofacial Sciences and Program in Craniofacial Biology, University of California San Francisco, San Francisco, CA, 94143, USA.
Yuwei CaoUniversity of California San Diego, Biomedical Sciences Graduate Program, La Jolla, CA, 92093, USA.
Alfredo A MolinoloGleiberman Head and Neck Cancer Center, Moores Cancer Center, University of California San Diego Health, La Jolla, CA, 92037, USA.
Kenneth KimLa Jolla Institute for Immunology, La Jolla, CA, 92037, USA.ORCID http://orcid.org/0000-0002-5993-4575
Kanako SakaguchiIDEXX Laboratories KK, Tokyo, 168-0063, Japan.
Joseph A CalifanoDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego Health, La Jolla, CA, 92037, USA.
Quinton SmithDepartment of Chemical and Biomolecular Engineering, University of California Irvine, Irvine, CA, 92697, USA.ORCID http://orcid.org/0000-0001-7079-1176
Alon GorenDivision of Medical Genetics, Department of Medicine, University of California San Diego, La Jolla, CA, 92093, USA.
Ophir D KleinDepartment of Orofacial Sciences and Program in Craniofacial Biology, University of California San Francisco, San Francisco, CA, 94143, USA.ORCID http://orcid.org/0000-0002-6254-7082
Pablo TamayoGleiberman Head and Neck Cancer Center, Moores Cancer Center, University of California San Diego Health, La Jolla, CA, 92037, USA.
J Silvio GutkindGleiberman Head and Neck Cancer Center, Moores Cancer Center, University of California San Diego Health, La Jolla, CA, 92037, USA. sgutkind@health.ucsd.edu.ORCID http://orcid.org/0000-0002-5150-4482

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
San Diego Biomedical Informatics Education & Research (SABER)T15LM011271 · NLM · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHAMIM NEMATI · 2012 to 2026
$9.7M
RESEARCH IN INFECTIOUS DISEASEST32AI007036 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIZET, VICTOR · 1985 to 2025
$9.2M
Targeting Signaling Vulnerabilities for Oral Cancer PreventionR01DE026644 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jorge Silvio Gutkind, SCOTT M LIPPMAN · 2017 to 2026
$4.7M
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck CancersU01DE028227 · NIDCR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI GUTKIND, JORGE SILVIO, RAO, ANJANA · 2018 to 2022
$4.6M
Mapping immuno-genomic drivers of the head and neck precancer invasive-disease transitionU01CA290479 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ludmil B Alexandrov, Jorge Silvio Gutkind · 2023 to 2026
$3.1M
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal MelanomaR01CA257505 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI APLIN, ANDREW ERIC, GUTKIND, JORGE SILVIO · 2021 to 2025
$2.7M
Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCCR01CA247551 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUTKIND, JORGE SILVIO · 2020 to 2024
$2.5M
Signal Transduction by PI3K/mTORR01DE030497 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUTKIND, JORGE SILVIO, ZHANG, JIN · 2021 to 2025
$2.4M
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision TherapyR01DE026870 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUTKIND, JORGE SILVIO · 2018 to 2022
$2.3M
OTOLARYNGOLOGY TRAINING IN IMMUN., VIROL. &MOLEC. BIOL.T32DC000028 · NIDCD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RYAN, ALLEN F. · 1989 to 2020
$2.1M
Multidisciplinary Educational Approach to Reducing Cancer DisparitiesR25CA221779 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUTKIND, JORGE SILVIO, SADLER, GEORGIA ROBINS · 2019 to 2023
$2.1M
EIF | Stand Up To Cancer (SU2C) 308268NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA247551NCI NIH HHS R01 CA257505NCI NIH HHS R25 CA221779NCI NIH HHS U01 CA290479NCRR NIH HHS S10 RR027366NIAID NIH HHS T32 AI007036NIDCD NIH HHS T32 DC000028NIDCR NIH HHS R01 DE026644NIDCR NIH HHS R01 DE026870NIDCR NIH HHS R01 DE030497NIDCR NIH HHS U01 DE028227NIH HHS S10 OD025052NLM NIH HHS T15 LM011271
6 · The paper itself

Abstract

Tumor initiation represents the first step in tumorigenesis during which normal progenitor cells undergo cell fate transition to cancer. Capturing this process as it occurs in vivo, however, remains elusive. Here we employ spatiotemporally controlled oncogene activation and tumor suppressor inhibition together with multiomics to unveil the processes underlying oral epithelial progenitor cell reprogramming into tumor initiating cells at single cell resolution. Tumor initiating cells displayed a distinct stem-like state, defined by aberrant proliferative, hypoxic, squamous differentiation, and partial epithelial to mesenchymal invasive gene programs. YAP-mediated tumor initiating cell programs included activation of oncogenic transcriptional networks and mTOR signaling, and recruitment of myeloid cells to the invasive front contributing to tumor infiltration. Tumor initiating cell transcriptional programs are conserved in human head and neck cancer and associated with poor patient survival. These findings illuminate processes underlying cancer initiation at single cell resolution, and identify candidate targets for early cancer detection and prevention.

Indexed as

Cellular ReprogrammingEpithelial CellsNeoplastic Stem CellsSingle-Cell AnalysisYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingAnimalsCarcinogenesisCell DifferentiationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansMiceSignal TransductionStem CellsAdaptor Proteins, Signal TransducingTOR Serine-Threonine KinasesTranscription FactorsYAP1 protein, humanYAP-Signaling Proteins

Identifiers

PMID39779672
PMCPMC11711616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.